Justification (Sole Source)Posted Jan 8, 2025

Limited Sources Justification (LSJ): Firm Fixed-Price, Non-Personal Service Type, Commercial Item DO/TO to provide Immunoassay Reagents, Supplies, and Cost Per Reportable Result Analyzer Services for the Standing Rock Service Unit (SRSU), IHS Hospital.

Indian Health Service · GREAT PLAINS AREA INDIAN HEALTH SVC

Stage
Justification for other than full competition
NAICS
424210
Value
Not stated
Solicitation
RFQ-25-001
Set-aside
None stated
PSC
6550
Place
Fort Yates, ND, USA
Contact
David Jones (david.jones@ihs.gov)
Loading your pipeline and notes…
CSV Email

Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.

Where this opportunity stands

Every notice posted under solicitation RFQ-25-001 in this department, oldest first.

Early notice
  • Nov 21, 2024
    Sources Sought
    Open
Solicitation
None posted
Award
  • Jan 8, 2025
    Award Notice
    ABBOTT LABORATORIES INC. · $22K
    Open
Other notices
  • Jan 8, 2025 · this notice
    Justification (Sole Source)

Next steps for this stage

Standard steps for the notice type; not advice about this buyer.

  • The agency intends to buy without full competition. Read the justification for the reason and the named source.

What the notice says

FAR 8.405-6(a)(1)(i)(B)); Only one source is capable of providing the supplies or services required at the level or quality required because the supplies or services are unique or highly specialized (FAR 8.405-6(a)(1)(i)(B)). The Abbott Architect i1000SR immunoanalyzer rental/service began in 2022. The analyzer is relatively new. Due to its proprietary nature, Abbott technicians are the only authorized personnel to work on the analyzer.

Who won similar work

3 award notices on SAM.gov in the last 24 months. Matched by: Same agency (Indian Health Service), same product/service code (PSC) 6550.

Single-winner award sizes (3): middle half $80K to $147K, median $80K; range $80K to $215K.

WinnerAwardsValueLast
ORTHO-CLINICAL DIAGNOSTICS, INC · $QDEL · $2.7B2$160KMay 28, 2025
GOVERNMENT SCIENTIFIC SOURCE INC1$215KSep 11, 2026

Value counts new single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling (same contract, or the same office, day and amount); that ceiling is not one company's win, so it is not added in. Contract modifications are not new awards and are not added in either. Revenue next to a ticker is the company's revenue over the latest 12 months in its SEC filings.

Investor context
  • $QDEL reported $2.7B revenue (12 months to Jun 28, 2026). The median single-winner award in these 3 past awards, $80K, is under 0.1% of that. SEC filing

One award's total value against one year of revenue; many awards are paid over several years.

Latest awards

Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.

Competitive landscape

For the 2 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.

  • 0 of these past winners lobbied Indian Health Service since 2024 (0 filings)
  • 0 of their lobbyists list a past Indian Health Service job
  • No corporate PAC money from them to the overseeing committees since 2024
  • 0 foreign-agent (FARA) registrations
See who and the source records with Pro

Policy around it

Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.

  • 0 bills named on the past winners' lobbying filings
  • 2 rules from the department in the last 12 months
  • 0 executive orders naming the agency in the last 12 months
See who and the source records with Pro

Market

For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.

  • 1 of the past winners are listed companies
  • 0 insider buys and 0 insider sells at them in the last 90 days
See who and the source records with Pro

Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.

Companies are matched to tickers by exact name, including the subsidiaries a company lists in its SEC filings. A company we could not match shows no market rows; that is a miss, not a finding.